Along these lines, experiments in rodents indicated that treatment with NAD (Pillai et al., 2010) and the RXRα agonist bexarotene (Zhu et al., 2014) protected against cardiac hypertrophy via activating LKB1-AMPK signaling. Here, PRKAA2 is linked to cardiac hypertrophy.